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Abstract 
Objective 
To investigate the longitudinal spinal cord and brain changes in neuromyelitis optica (NMO) and 
multiple sclerosis (MS), and its association with disability progression. 
Patients and Methods 
We recruited 28 NMO, 22 MS and 20 healthy controls (HC), who underwent both spinal cord 
and brain MRI at baseline. 25 NMO and 20 MS completed 1-year follow up. Baseline spinal cord 
and brain lesion loads, mean upper cervical cord area (MUCCA), brain, and thalamus volume 
and their changes during a 1-year follow-up were measured and compared between groups. All 
the measurements were also compared between progressive and non-progressive groups in 
NMO and MS. 
Results 
MUCCA decreased significantly during the 1-year follow-up in NMO not in MS. Percentage brain 
volume changes (PBVC) and thalamus volume changes in MS were significantly higher than 
NMO.MUCCA changes were significantly different between progressive and non-progressive 
groups in NMO, while baseline brain lesion volume and PBVC were associated with disability 
progression in MS. MUCCA changes during 1-year follow-up showed association with clinical 
disability in NMO. 
Conclusion  
Spinal cord atrophy changes were associated with disability progression in NMO, while baseline 
brain lesion load and whole brain atrophy changes were related to disability progression in MS. 
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Key point 1:Spinal cord atrophy progression was observed in NMO. 
Key point 2:Spinal cord atrophy changes were associated with disability progression in NMO. 
Key point 3Brain lesion and atrophy were related to disability progression in MS. 
 
Abbreviations: HC: healthy control; MUCCA: mean upper cervical cord area; NBV: normalized 
brain volume; NMO: neuromyelitis optica; NTV: normalized thalamic volume; PBVC: percentage 
brain volume changes; PVVC: percentage ventricular volume change; RRMS: relapsing remitting 
MS 
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Introduction 
Neuromyelitis optica  (NMO) is an autoimmune inflammatory disease of the central nervous 
system. This syndrome is characterized clinically by recurrent attacks of optic neuritis and 
myelitis [1-3] and now considered as a primary astrocytopathy [4; 5]caused by pathogenic 
antibodies to aquaporin-4 (AQP-4) water channels that are concentrated on the foot processes 
of astrocytes[6]. Clinically, accurate diagnosis of MS and NMO is critical especially in the early 
stage, since the prognosis and treatments of these disorders differ[1], and some MS treatments 
(including interferon-β and Fingolimod) may exacerbate NMO[7-9].   
 
The major MRI feature of NMO is spinal cord pathology, particularly longitudinally extensive 
lesions and atrophy[1; 3]. Subtle, regional brain atrophy has also been reported in NMO [10-
12]. A recent cross-sectional study showed association between spinal cord but not brain 
atrophy and clinical disability in NMO[13]. However, longitudinal changes of brain and spinal 
cord atrophy, and their correlations with clinical worsening in NMO are unknown. 
 
In contrast to NMO, MRI has been used extensively to measure longitudinal changes in global 
and regional brain volumes in multiple sclerosis (MS)[14]. Whole brain and thalamic atrophy, as 
well as spinal cord atrophy progression have been found to correlate with clinical 
worsening[15-17]. We therefore investigated these MRI biomarkers as predictors of disability 
worsening in NMO patients. 
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This study evaluated the longitudinal changes of spinal cord MRI measurements including cord 
lesions and cord atrophy, using the mean upper cervical cord area (MUCCA) [18], together with 
brain MRI measurements including white matter lesions, whole brain and thalamus volume in 
AQP4 positive NMO patients over 1 year and correlated these changes with clinical disability 
changes. A cohort of MS patients served as a comparator.  
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Materials and Methods 
Standard protocol approvals, registrations, and patient consents 
The institutional review board of *BLINDED* approved the study and written informed consent 
was obtained from each participant prior to participation. 
 
Participants 
Twenty-eight relapsing NMO patients were recruited from *BLINDED*. The diagnosis of NMO 
was determined according to the revised diagnostic criteria[2]. All patients had optic neuritis 
and myelitis, and met 2 of the 3 supporting criteria including AQP4 antibody positivity, T2 
weighted brain MRI non-diagnostic for MS, and a spinal cord lesion involving at least three 
vertebral segments. For comparison with the NMO patients, we recruited 22 relapsing-
remitting MS (RRMS) patients fulfilling the McDonald criteria [19], matched for age, sex, disease 
duration and EDSS score to the NMO group. To exclude the confounding effect of edema or 
medication on the spinal cord measurements, all of the participating patients had been relapse-
free and without treatment with disease-modifying medications or steroid within 4 weeks 
before the MRI scans being obtained. Twenty-five NMO patients and 20 MS patients completed 
a 1-year follow-up. During the 1-year follow-up, three NMO patients and five MS patients had 
at least one relapses, the maximal number of relapses in a single patient was two. The main 
demographic and clinical characteristics of the patients were shown in Table 1.  
We also recruited 20sex- and age-matched healthy controls (HC) with no current or previous 
history of neurological dysfunction and no visible abnormalities on T2 weighted MRI (Table 1).  
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To exclude the possible diagnostic confounders of AQP4 negative NMO patients, all included 
patients with NMO were anti- AQP4 antibody positive (using an indirect immunofluorescence 
method[20]).At follow-up, patients were classified as clinically worse if they had an EDSS score 
increase ≥1.0, when baseline EDSS was <6.0 or an EDSS score increase≥0.5, when baseline EDSS 
was ≥6.0.[21]The median follow-up length was 1.2 years (range 0.9 –3.0 years). 
 
MRI Acquisition 
Imaging was performed on a 1.5 T scanner (Sonata; Siemens Medical Systems, Erlangen, 
Germany) at *BLINDED*. MRI scans of the brain and cervical cord from all patients were 
obtained at study entry and follow-up, using the same MRI machine, which did not undergo any 
upgrade during the study period and was under a regular program of maintenance. 
At follow-up, patients were repositioned following published guidelines[22]. During each 
session, the following sequences were acquired: 
 
Brain MRI: 
Axial slices were positioned parallel to line that joins the AC-PC line, with in plane resolution of 
1×1mm2, 30 slices, 4 mm slice thickness (10% gap) and included T2-weighted turbo spin-echo 
(repetition time[TR]=5500ms, echo time[TE]=94ms, number of signals acquired=3, echo train 
length=11) and FLAIR (TR/TE=8500/150, inversion time[TI]=2200ms, number of signals 
acquired=3, echo train length=8).  Sagittal 3D T1-weighted magnetization-prepared rapid 
acquisition gradient echo (MPRAGE) (TR/TE = 1970/3.9ms, TI = 1100ms, flip angle (FA) = 15◦, 
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slice thickness= 1.7mm, with in plane resolution of 1×1mm2) images were also obtained to 
measure brain volume and MUCCA measurement. 
 
Spinal cord MRI: 
Cervical and thoracic spinal cord imaging included 3-mm-thick sagittal sections and 4-mm-thick 
axial sections using T2-weighted and proton density (PD) sequences (in-plane resolution 1 
mm2).  
 
Image Analysis 
Marking and measurement of hyperintense brain lesions (T2LV) on baseline and one year 
follow up T2-weighted was performed by an experienced neuroradiologist (*BLINDED*) using 
MRIcro software (http://www.mccauslandcenter.sc.edu/mricro/mricro/mricro.html), using 
FLAIR images for reference. 
 
As the NMO patients had no lesions or only non-specific white matter abnormalities, T2LV was 
not measured in NMO patients. Using T2-weighted spinal cord images, the number and total 
length of spinal cord lesions were marked and counted in all patients. The total lesion length in 
each NMO and MS patient was calculated by adding the cranio-caudal length of each spinal 
cord lesion on sagittal MR images. 
 
Baseline and longitudinal whole brain, thalamus volume measures 
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Baseline normalized whole-brain (NBV) were computed using the 3D T1-weighted images and 
SIENAX (part of FSL 5.0.4, http://www.fmrib.ox.ac.uk/fsl)[23]. Thalamus volumes were 
quantified by FMRIB Integrated Registration and Segmentation Tool (FIRST) [24](also part of 
FSL). The left and right thalamic volumes were averaged and normalized by the V-scaling from 
SIENAX. 
Percentage whole brain change (PBVC) was analyzed using the semi-automated software 
SIENA[25; 26]. Using an adaptation of SIENA, we calculated central atrophy rate as percentage 
ventricular volume change by VIENA[26], where only brain/non-brain edge points on the 
ventricular edges were selected and their mean edge displacement was calculated. The 
percentage change of thalamus volumes between two time points was numerically determined. 
 
Baseline and longitudinal MUCCA measurements 
For each time point, MUCCA was measured by the same neuroradiologist (*BLINDED*), blinded 
to the date of the MRI, using the sagittal 3D T1-weighted brain images (with upper cervical cord 
coverage). MUCCA was measured using a semi-automated segmentation method over a 
predefined 30mm section length (NeuroQLab; Fraunhofer MEVIS, Bremen, Germany). The 
workflow and the reliability of the software were described previously[18; 27; 28]. Overview of 
the image-processing pipeline of MUCCA measurement was illustrated in figure 1. The 
percentage change of MUCCA between two time points was calculated using two cross-sectional 
scans. 
 
Statistical Analysis 
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Analyses were performed using SPSS software (Version 18; SPSS, Chicago, Ill). Kolmogorov-
Smirnov tests were performed together with visual inspection of histograms to assess normality 
of the variables, and Levene's test was performed to test homogeneity of the variables. For 
normally distributed variables with homogeneity of variance, one-way analysis of covariance 
(Bonferroni test used for post-hoc comparisons) or a two-sample t test was performed to 
examine group effects. For variables that were not normally distributed, the Wilcoxon rank sum 
test or Kruskal-Wallis test was used. A binary logistic regression model was used to investigate 
the role of clinical and MRI measurements as independent predictors of EDSS worsening at 
follow-up. 
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Results 
Baseline demographics, clinical and MRI characteristics 
As shown in Table 1, no significant differences were observed in age and sex among the 3 
groups (NMO, MS and HC). EDSS, number of relapses, and disease duration showed no 
significant differences between MS and NMO groups.  
 
The median cord lesion number in NMO patients was 1 (range 1-3), and the median total lesion 
length was 4vertebral segments (range 3-10). In MS patients, spinal cord lesions were present 
in 19 patients (19/20, 95%), with a median of 2 lesions per patient (range 0-6), and a median 
total lesion length of 1 vertebral segment (range 0-4). The median brain T2LV in MS patients 
was 98ml. 
 
There were no significant differences between baseline NBV between the three study groups, 
however normalized thalamic volume (NTV) was significantly lower in MS patients when 
compared to controls (p=0.04).No difference of NTV was observed between MS and 
NMO(p>0.1). NMO patients showed a lower MUCCA than HC (p<0.01) and a trend for lower 
MUCCA compared to MS (p=0.05). No significant difference was identified between MS and HC 
in MUCCA (p=0.28). 
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Longitudinal brain and spinal cord lesion load changes 
Both in MS and NMO, no significant changes were observed in spinal cord or brain lesion loads 
between baseline and follow-up. 
 
Longitudinal brain volume and MUCCA changes 
Within the NMO cohort, the baseline (0.65±0.10 cm2) MUCCA decreased slightly atone year 
follow-up(0.64±0.08 cm2, p=0.003), while NBV and NTV did not change significantly (p>0.05). 
 In MS, only NTV significantly decreased during follow-up (baseline:10.28±1.38 ml; follow-
up9.98±1.42 ml; p<0.001), while the whole brain volume and MUCCA measures did not change 
significantly (p>0.1). 
The PBVC and NTV changes were significantly greater in MS compared to NMO (p=0.03, p=0.02 
respectively), while no significant differences in MUCCA changes were observed between NMO 
and MS.(Table2).  
 
 
Association between brain lesions, volume, MUCCA and clinical measurements 
No significant correlations between longitudinal changes of brain measurement and MUCCA 
were observed in either NMO or MS. We haven’t found We found a significant correlation 
between PVVC (percentage ventricular volume change) and disease duration in MS (r=-0.478, 
p=0.033). No correlations were identified between other clinical measurements and baseline 
values or changes of brain volume or MUCCA in both NMO and MS. (all p>0.1). 
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Determinants of disability progression 
Within the NMO cohort, the only significant difference between progression and non-
progression groups was the magnitude of change in MUCCA. In MS, PBVC and baseline lesion 
volume were significantly different between progressive and non-progressive groups (Table 3 
and Figure 2). In a multivariable logistic regression with disease progression over 1 year as a 
binary dependent variable, percentage changes of MUCCA in NMO (Odd ratio 0.671 
95%CI:0.458-0.982, p=0.04) remained significant. After adding the number of relapse as a 
covariant in the analysis, the results of differences between MS and NMO, and between 
progression and non-progression groups were unchanged. 
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Discussion 
In this study, we demonstrated significant longitudinal changes of MUCCA during one year of 
follow up in NMO, while significant thalamic volume changes were identified in MS.  
In NMO, spinal cord atrophy progression was associated with clinical worsening, while baseline 
WM lesion volume and whole brain atrophy changes assessed by PBVC were associated with 
disability progression in MS. In a binary logistic multivariable model predicting EDSS progression 
over the course of 1 year, MUCCA remained a significant variable in NMO, whereas no imaging 
variables remained significant in MS. 
 
At baseline, atrophy patterns of brain and spinal cord differed between NMO and MS patients. 
NMO patients showed spinal cord atrophy without brain atrophy, while MS patients exhibited 
whole brain and thalamus atrophy, but no significant spinal cord atrophy compared to HC, 
consistent with previous studies [13; 28].  
 
For the longitudinal results, no significant whole brain or thalamic atrophy changes were 
identified in NMO, implying that rate of brain neurodegeneration is very limited in NMO during 
short-term follow-up, in line with a previous longitudinal NMO study [29]. However, this finding 
need to be confirmed in a larger sample with longer follow-up, since pathology studies[30] 
reveal pathological processes consisting not only of inflammatory lesions characterized by loss 
of astrocytic AQP4 immunoreactivity, but also cortical degeneration in NMO brains. Significant 
MUCCA changes were observed during 1 year follow-up, implying spinal cord atrophy 
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measurement is more sensitive, and probably also much more consistent, than brain atrophy 
measurement in NMO. The likely pathological mechanisms of upper cervical spinal cord volume 
loss is axonal degeneration, demyelination, necrosis and cavitation[1].In contrast, MS patients 
showed progressive thalamic atrophy, but not whole brain atrophy or spinal cord atrophy 
between baseline and follow-up, suggesting thalamus volume as a more sensitive measurement 
than whole brain volume or spinal cord volume to detect neurodegeneration in a relatively 
small sample of MS patients.  This finding is consistent with previous studies showing thalamic 
atrophy as a key marker of disease progression[31]. 
 
The role of spinal cord atrophy in predicting the accumulation of disability in NMO patients has 
been already suggested by previous cross-sectional study[13]. The current longitudinal study 
extends these findings in an independent dataset, with the only difference between disability 
progression and non-progressive group in NMO being MUCCA changes. In the binary logistic 
regression model, MUCCA was the only variable to predict clinical worsening. Together with the 
results from the prior cross sectional study, our finding emphasizes the role of spinal cord 
atrophy in disability worsening in NMO, suggesting that MUCCA change could serve as a 
biomarker to predict rate of disability worsening. In this short-duration study we did not find 
any association between MUCCA changes and disability change in MS, in line with other studies 
in patients with RRMS showing no association between MUCCA change and clinical 
progression[16]. Spinal cord and brain atrophy changes were not correlated with each other in 
either NMO or MS patients, suggesting cord atrophy may occur partly independently from brain 
volume change during the disease progression in both diseases. No significant differences in 
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demographic and clinical measurements were observed between progression and non-
progression groups in either NMO or MS.  
 
Some limitations of our study have to be mentioned. First, we didn’t follow up the HC, which 
prevented any comparison of brain and spinal cord changes between patients and HC. However 
the observed decrease of MUCCA and brain atrophy over time in patients is highly likely to be a 
disease related effect, as in the normal population significant spinal cord atrophy were not 
observed in young subjects, and the mean age of the healthy subjects in the current study is 35 
years[32].  Second, MUCCA and thalamic atrophy rates were derived from two separated 
segmentations. Optimal registration-based methods may lead to a more precise estimation of 
longitudinal changes in future studies. Third, we did not normalize the MUCCA measurements 
since there is no consensus on spinal cord atrophy normalization. Fourth, this study is a 
preliminary study with a relatively small sample size and short follow-up period, and no 
correction for multiple testing was performed; additionally a small proportion of the patients 
had relapse during the follow-up, we can’t fully exclude the effect of relapse on the results; 
therefore further studies with larger sample sizes and longer term follow up are warranted to 
confirm our results. Finally, to further improve the clinical correlation or future clinical trials in 
NMO and MS, other MRI measurements should be explored and integrated such as diffusion 
metrics [33], functional MRI [34] in both brain and spinal cord, as well as structural and 
diffusion measurements of the optic nerve [35]. 
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Conclusion 
Different patterns of longitudinal brain and spinal cord changes were identified in NMO and 
MS. Spinal cord atrophy progression was observed in NMO, while thalamus atrophy progression 
was identified in MS. Spinal cord atrophy changes were associated with disability progression in 
NMO, while baseline brain lesion load and whole brain atrophy changes were related to 
disability progression in MS. 
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Tables and figures 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1. Baseline, Demographic, clinical characteristics and brain, spinal cord volume measurement 
 NMO MS HC p value 
N 25 20 20 / 
Sex 4M/21F 5M/15F 5M/15F 0.46 a 
Age (years) 35.6±9.9  
(22-56) 
35.5±10.6 
(18-54) 
34.6±10.0  
(22-59) 
0.93 b 
EDSS 3.5 
(0.5-7) 
2.5 
(0-6.5) 
/ 0.06c 
Disease Duration (years) 4.0±2.8 
(0.60-16.00) 
3.7±2.5 
(0.60-15.00) 
/ 0.51d 
Number of relapses 3 
(2-9) 
3 
(1-7) 
 0.45c 
T2LV (ml) / 98 
(1.3; 1943) 
/ / 
NBV(L) 1.54±0.75 
(1.31-1.67) 
1.51±0.76* 
(1.40-1.67) 
1.59±0.18 
(1.34-1.88) 
<0.01b 
Thalamus volume (ml) 10.5±1.2 
(8.4-12.8) 
10.3±1.4* 
(8.3-13.7) 
11.2±1.0 
(8.3-13.7) 
0.03b 
Total spinal cord lesion 
number 
1 
(1-3) 
2 
(0-6) 
/ 0.145c 
Total spinal cord lesion 
length 
4 
(3-10) 
1 
(0-4) 
/ <0.001c   
MUCCA (cm2) 0.69±0.07* 
(0.54-0.84) 
0.72±0.07 
(0.60-0.86) 
0.78±0.07 
(0.65-0.93) 
<0.001b 
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Data are presented as mean±SD (range) or median (range) except for gender.  
Abbreviations: EDSS: Expanded Disability Status Scale; MS=multiple sclerosis; MUCCA=mean upper cervical cord 
area; T2LV =T2 lesion volume; NBV = normalized brain volume; NMO = neuromyelitis optica 
ap-value was obtained by chi-square test. 
bp-value was obtained by one-way ANOVA. Post hoc analysis was performed using Bonferroni correction. 
cp-value was obtained by Kruskal-Wallis test. 
dp-value was obtained by two-sample t-test. 
*p<0.05 compared to healthy controls 
 
 
 
 
 
 
 
 
Table 2. Longitudinal changes brain, spinal cord lesions and volume measurements 
 NMO MS P value 
Brain    
T2LV changes (%) / 1.36±20.43 
(-69.15;51.56) 
/ 
PBVC (%) -0.15±0.97 
(-2.08;2.15) 
-1.09±1.85 
(-6.20;1.19) 
0.03 
PVVC (%) 3.66±3.13 
(-1.69;10.9) 
5.56±7.34 
(-1.29;27.2) 
0.24 
Thalamus changes (%) -0.75±1.96 
(-5.58;4.44) 
-2.99±3.29 
(-7.68;4.51) 
0.01 
Spinal cord    
Total Lesion number changes 0 
(-2;1) 
1 
(-2;2) 
0.59 
Total Lesion length changes -0.5 
(-2;2) 
0.5 
(-1;2) 
0.08 
MUCCA changes(%) -1.92±3.00 
(-8.35;2.10) 
-0.83±2.04 
(-4.85;2.19) 
0.18 
 
Data are presented as mean±SD (range) or median (range) depending on the normality of the data 
Abbreviations: EDSS: Expanded Disability Status Scale; MS=multiple sclerosis; MUCCA=mean upper cervical cord 
area; T2LV = T2 lesion volume; NBV = normalized brain volume; NMO = neuromyelitis optica 
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Table 3. Clinical and MRI characteristics of patients with NMO and MS, separated according to disease progression after 1 year 
follow up 
 NMO MS 
 No  
progression 
N=18 
Progression 
N=7 
p value No 
progression 
N=15 
Progression 
N=5 
p value 
Age  36.0±10.7  
(24-56) 
34.4±8.0  
(22-48) 
0.73 37.3±10.7  
(24-56) 
30.0±9.6 
(24-56) 
0.19 
Gender 2/16 2/5 0.29 3/12 1/4 0.72 
EDSS  3.3±1.1 
(1-5.5) 
3.7±1.6 
(2-6) 
0.50 2.6±1.2 
(0.5-5.5) 
3.2±0.3 
(2-6) 
0.30 
Disease duration 
(years) 
4.3±3.1 
(0.6-11.0) 
3.6±2.0 
(2.0-7.0) 
0.59 3.3±2.1 
(1.0-8.0) 
4.5±2.6 
(2.0-6.0) 
0.30 
Number of 
relapses 
3.6±2.0 
(2-9) 
4.4±2.1 
(2-8) 
0.34 3.2±1.5 
(1-5) 
3.8±2.2 
(2-7) 
0.49 
Brain       
T2LV baseline 
(ml) 
   75 
(1.3-288) 
170 
(117-1943) 
0.03 
T2LV changes (%)    -2.08±19.29 
(-69.19-9.35) 
11.68±22.43 
(-1.68-51.56) 
0.20 
NBV(baseline) 1.53±0.08 
(1.31-1.63) 
1.56±0.06 
(1.48-1.67) 
0.39 1.52±0.08 
(1.40-1.67) 
1.47±0.06 
(1.40-1.56) 
0.25 
PBVC (%) -0.15±0.73 
(-2.08-0.87) 
-0.14±1.49 
(-2.08-2.15) 
0.98 -0.51±1.42 
(-4.99-1.19) 
-2.81±2.10 
(-6.20;-0.94) 
0.01 
  25 
PVVC(%) 3.31±2.96 
(-1.69-10.96) 
4.55±3.61 
(-0.71-9.13) 
0.38 6.39±7.86 
(-1.29-27.28) 
3.06±4.68 
(-0.86-9.32) 
0.39 
Thalamus 
Baseline (ml) 
10.5±1.3 
(8.5-12.8) 
10.5±1.0 
(8.4-11.5) 
0.92 10.5±1.4 
(8.6-13.8) 
9.7±1.6 
(8.3-11.7) 
0.32 
Thalamus volume 
changes 
-0.67±2.28 
(-5.58;4.44) 
-0.96±0.75 
(-3.34;-0.1) 
0.75 -2.27±3.35 
(-7.32;4.51) 
-5.12±2.14 
(-7.68;-2.67) 
0.09 
Spinal cord       
Total Lesion 
number(baseline) 
1 
(1;3) 
1 
(1;2) 
0.59 2 
(0;5) 
2 
(0;4) 
0.58 
Total Lesion 
number(changes) 
0 
(-1;1) 
0 
(-1;1) 
0.50 0 
(-2;3) 
0 
(0;3) 
0.16 
Total Lesion 
length (baseline) 
6 
(3-12) 
5 
(3;11) 
0.64 1 
(0;3) 
1.5 
(0;3)  
0.66 
Total Lesion 
length(changes) 
-1 
(-4;2) 
-1 
(-3;2) 
0.82 0 
(-2-3) 
1 
(0-5) 
0.11 
MUCCA(baseline) 0.68±0.07 
(0.53;0.79) 
0.72±0.08 
(0.61;0.84) 
0.17 0.72±0.06 
(0.60-0.83) 
0.75±0.09 
(0.64-0.86) 
0.42 
MUCCA(changes) -1.10±2.41 
(-8.35;2.10) 
-4.02±3.51 
(-7.86;1.97) 
0.03 -0.80±2.24 
(-4.85-2.19) 
-0.94±1.49 
(-3.23-0.29) 
0.90 
Data are presented as mean±SD (range) or median (range) depending on the normality of the data 
Abbreviations: EDSS: Expanded Disability Status Scale; MS=multiple sclerosis; MUCCA=mean upper cervical cord 
area; T2LV = T2 lesion volume; NBV = normalized brain volume; NMO = neuromyelitis optica 
 
 
Figure Legends: 
 
Figure 1. Overview of the image-processing pipeline of upper spinal cord area measurement  
 
 
 
Figure 2:The significant differences of MRI measurements between progression and no 
progression groups in NMO and MS. 
Abbreviations: KDE=kernel density estimation; MS=multiple sclerosis; MUCCA=mean upper 
cervical cord area; T2LV = T2 lesion volume; NMO = neuromyelitis optica; PBVC=percentage 
brain volume changes. 
